Literature DB >> 2902928

A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype.

H A Ingraham1, R P Chen, H J Mangalam, H P Elsholtz, S E Flynn, C R Lin, D M Simmons, L Swanson, M G Rosenfeld.   

Abstract

Multiple related cis-active elements required for cell-specific activation of the rat prolactin gene appear to bind a pituitary-specific positive transcription factor(s), referred to as Pit-1. DNA complementary to Pit-1 mRNA, cloned on the basis of specific binding to AT-rich cell-specific elements in the rat prolactin and growth hormone genes, encodes a 33 kd protein with significant similarity at its carboxyl terminus to the homeodomains encoded by Drosophila developmental genes. Pit-1 mRNA is expressed exclusively in the anterior pituitary gland in both somatotroph and lactotroph cell types, which produce growth hormone and prolactin, respectively. Pit-1 expression in heterologous cells (HeLa) selectively activates prolactin and growth hormone fusion gene expression, suggesting that Pit-1 is sufficient to confer a characteristic pituitary phenotype. The structure of Pit-1 and its recognition elements suggests that metazoan tissue phenotype is controlled by a family of transcription factors that bind to related cis-active elements and contain several highly conserved domains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902928     DOI: 10.1016/0092-8674(88)90038-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  196 in total

Review 1.  Other transcription factors and hypopituitarism.

Authors:  Laurie E Cohen; Sally Radovick
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

2.  Structure, alternative splicing and chromosomal localization of the cystatin-related epididymal spermatogenic gene.

Authors:  G A Cornwall; N Hsia; H G Sutton
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  Hoxa 11 is upstream of Integrin alpha8 expression in the developing kidney.

Authors:  M Todd Valerius; Larry T Patterson; Yuxin Feng; S Steven Potter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

4.  Specification of unique Pit-1 activity in the hGH locus control region.

Authors:  Brian M Shewchuk; Stephen A Liebhaber; Nancy E Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

Review 5.  Endocrine pathology in translational medicine: an overview of current and future prospects.

Authors:  Robert Yoshiyuki Osamura; Nobue Kumaki; Hiroshi Kajiwara; Noboru Egashira; Syunsuke Miyai; Susumu Takekoshi; Masanori Yasuda; Shinobu Umemura
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  Hormonal regulation of the thyrotropin beta-subunit gene by phosphorylation of the pituitary-specific transcription factor Pit-1.

Authors:  H J Steinfelder; S Radovick; F E Wondisford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

7.  A novel POU homeodomain gene specifically expressed in cells of the developing mammalian nervous system.

Authors:  R G Collum; P E Fisher; M Datta; S Mellis; C Thiele; K Huebner; C M Croce; M A Israel; T Theil; T Moroy
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

8.  The Oct-1 POU domain mediates interactions between Oct-1 and other POU proteins.

Authors:  C P Verrijzer; J A van Oosterhout; P C van der Vliet
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

Review 9.  From panhypopituitarism to combined pituitary deficiencies: do we need the anterior pituitary?

Authors:  Catherine Carrière; Anatoli Gleiberman; Chijen R Lin; Michael G Rosenfeld
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

10.  Mouse Brn-3 family of POU transcription factors: a new aminoterminal domain is crucial for the oncogenic activity of Brn-3a.

Authors:  T Theil; S McLean-Hunter; M Zörnig; T Möröy
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.